Leadership Changes

Summary by AI BETAClose X

4basebio PLC has appointed Dr. Amy Walker as its new Chief Executive Officer, succeeding founder Dr. Heikki Lanckriet, who will lead a new entity focused on the Hermes nanoparticle platform and remain on the Board. David Roth will also step down as Chief Financial Officer to join the new venture. Dr. Walker, previously Chief Operating Officer, is expected to drive an accelerated commercial growth strategy, focusing on the synthetic DNA market as customers increasingly seek alternatives to plasmid DNA, building on the company's recent GMP milestone. This leadership transition occurs as 4basebio anticipates significant commercial growth in 2026, supported by top-tier pharma clients and a growing pipeline.

Disclaimer*

Companies

4basebio (4BB)
UK 100

Latest directors dealings